Benitec Biopharma Inc. (BNTC): Price and Financial Metrics


Benitec Biopharma Inc. (BNTC): $0.23

0.00 (-0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNTC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BNTC Stock Summary

  • BENITEC BIOPHARMA INC's market capitalization of $6,435,667 is ahead of merely 1.61% of US-listed equities.
  • Revenue growth over the past 12 months for BENITEC BIOPHARMA INC comes in at 1,725%, a number that bests 99.34% of the US stocks we're tracking.
  • BENITEC BIOPHARMA INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -277.89%, greater than the shareholder yield of merely 1.96% of stocks in our set.
  • Stocks that are quantitatively similar to BNTC, based on their financial statements, market capitalization, and price volatility, are ANGN, PTN, BGRY, SABS, and LCTX.
  • BNTC's SEC filings can be seen here. And to visit BENITEC BIOPHARMA INC's official web site, go to www.benitec.com.

BNTC Valuation Summary

  • BNTC's price/sales ratio is 89; this is 1645.1% higher than that of the median Healthcare stock.
  • Over the past 90 months, BNTC's price/sales ratio has gone up 72.3.

Below are key valuation metrics over time for BNTC.

Stock Date P/S P/B P/E EV/EBIT
BNTC 2023-01-20 89.0 0.4 -0.4 0.5
BNTC 2023-01-19 82.2 0.4 -0.3 0.5
BNTC 2023-01-18 86.3 0.4 -0.3 0.5
BNTC 2023-01-17 84.9 0.4 -0.3 0.5
BNTC 2023-01-13 89.0 0.4 -0.4 0.5
BNTC 2023-01-12 76.7 0.4 -0.3 0.6

BNTC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BNTC has a Quality Grade of F, ranking ahead of 1.09% of graded US stocks.
  • BNTC's asset turnover comes in at 0.004 -- ranking 417th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows BNTC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 1 -36.612
2020-06-30 0.007 1 -8.634
2019-06-30 0.718 1 2.070
2018-06-30 0.214 1 -3.387
2017-06-30 0.521 1 -2.375
2016-06-30 0.020 1 -18.246

BNTC Price Target

For more insight on analysts targets of BNTC, see our BNTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 2 (Hold)

BNTC Stock Price Chart Interactive Chart >

Price chart for BNTC

BNTC Price/Volume Stats

Current price $0.23 52-week high $3.05
Prev. close $0.23 52-week low $0.13
Day low $0.22 Volume 97,600
Day high $0.24 Avg. volume 307,200
50-day MA $0.19 Dividend yield N/A
200-day MA $0.67 Market Cap 6.40M

Benitec Biopharma Inc. (BNTC) Company Bio


Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.


BNTC Latest News Stream


Event/Time News Detail
Loading, please wait...

BNTC Latest Social Stream


Loading social stream, please wait...

View Full BNTC Social Stream

Latest BNTC News From Around the Web

Below are the latest news stories about BENITEC BIOPHARMA INC that investors may wish to consider to help them evaluate BNTC as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | January 12, 2023

Analysts Say Benitec Biopharma Inc. (NASDAQ:BNTC) Can Really Get To $4.00 In 12 Months

In last trading session, Benitec Biopharma Inc. (NASDAQ:BNTC) saw 0.4 million shares changing hands with its beta currently measuring 1.22. Company’s recent per share price level of $0.13 trading at -$0.02 or -12.00% at ring of the bell on the day assigns it a market valuation of $3.77M. That closing price of BNTC’s stock is … Analysts Say Benitec Biopharma Inc. (NASDAQ:BNTC) Can Really Get To $4.00 In 12 Months Read More »

Marketing Sentinel | December 17, 2022

Was anything positive for Benitec Biopharma Inc. (BNTC) stock last session?

As of Wednesday, Benitec Biopharma Inc.’s (NASDAQ:BNTC) stock closed at $0.19, up from $0.18 the previous day. While Benitec Biopharma Inc. has overperformed by 5.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BNTC fell by -93.67%, with highs and lows ranging from $3.34 to $0.13, […]

US Post News | November 24, 2022

Analysts Are Bullish on These Healthcare Stocks: Benitec Biopharma (BNTC), Moderna (MRNA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Benitec Biopharma (BNTC – Research Report) and Moderna (MRNA – Research Report) with bullish sentiments. Benitec Biopharma (BNTC) In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Benitec Biopharma, with a price target of $4.00. The company's shares closed last Thursday at $0.16, close to its 52-week low of $0.13. According to TipRanks.

Catie Powers on TipRanks | November 10, 2022

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S. Securities and Exchange Commission.

GlobeNewswire | November 10, 2022

Read More 'BNTC' Stories Here

BNTC Price Returns

1-mo 38.97%
3-mo 19.29%
6-mo -71.95%
1-year -90.69%
3-year -96.77%
5-year -99.58%
YTD 35.29%
2022 -93.51%
2021 -12.67%
2020 -60.78%
2019 -66.00%
2018 -49.32%

Continue Researching BNTC

Want to see what other sources are saying about Benitec Biopharma LTD's financials and stock price? Try the links below:

Benitec Biopharma LTD (BNTC) Stock Price | Nasdaq
Benitec Biopharma LTD (BNTC) Stock Quote, History and News - Yahoo Finance
Benitec Biopharma LTD (BNTC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6283 seconds.